← Back to Clinical Trials
Recruiting NCT06904495

NCT06904495 Assessment of Sleep Quality in Patients Treated for Cancer Between 15 and 24 Years of Age

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06904495
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Nice
Condition Cancer Survivors
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2025-04-15
Primary Completion 2026-05-05

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 24 Years
Study Type INTERVENTIONAL
Interventions
Survey of sleep quality and associated factors

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2025-04-15 with a primary completion date of 2026-05-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Medical professionals now take into account the specificities of the care and support of Adolescents and Young Adults (AYAs). Cancer aftermaths in patients diagnosed during the AYA period are also known: the consequences of chemotherapy and radiotherapy treatments on a growing organism, the difficulty of some follow-ups, the longevity, and the delayed occurrence of certain complications. In the general population, sleep disorders affect 40% of adolescents. About 30% of pediatric cancer survivors experience fatigue they attribute to their cancer, even years after the end of their treatment. The sleep quality of patients treated for cancer when they were AYAs, and the eventual care of sleeping disorders, are poorly studied. The investigators suppose that the oncologic treatment during this particular life stage, when sleeping disorders are already present and multifactorial, could have long-term impacts on sleep. The investigators offer to evaluate, through a questionnaire filled out by patients treated for cancer in the AYA period, the frequency of moderate to severe insomnia.

Eligibility Criteria

Inclusion Criteria: * Patient treated for a cancer * Patient aged between 15 and 24 years old at the time of the diagnosis * Patients whom intensive treatment ended at least 3 months ago * Patient followed in a PACAAURA cancerology center * Life expectancy ≥ 6 months * Karnosky index \> 60% * Patient who agrees to participate in the program and benefits from social security * Patient able to understand, speak and read French. * No major cognitive impairment (assessed by the patient's referees) * No sensory disability Exclusion Criteria: * Patient unable to use informatic tools * Known superior cognitive function disorders * Progressive psychiatric pathology * Drug user or alcohol abuse

Contact & Investigator

Central Contact

Meryl Horwitz, Dr

✉ horwitez.m@chu-nice.fr

📞 492036795

Frequently Asked Questions

Who can join the NCT06904495 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 24 Years, studying Cancer Survivors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06904495 currently recruiting?

Yes, NCT06904495 is actively recruiting participants. Contact the research team at horwitez.m@chu-nice.fr for enrollment information.

Where is the NCT06904495 trial being conducted?

This trial is being conducted at Nice, France.

Who is sponsoring the NCT06904495 clinical trial?

NCT06904495 is sponsored by Centre Hospitalier Universitaire de Nice. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology